What is BNT162b4 15 mcg used for?

BNT162b4 15 mcg is indicated for COVID-19 prevention.

Who makes BNT162b4 15 mcg?

BNT162b4 15 mcg is developed by Pfizer.

What development phase is BNT162b4 15 mcg in?

BNT162b4 15 mcg is FDA-approved (marketed).

What is the generic name of BNT162b4 15 mcg?

bnt162b4-15-mcg is the generic (nonproprietary) name of BNT162b4 15 mcg.

Last reviewed 2026-04-20 · How we verify

BNT162b4 15 mcg (bnt162b4-15-mcg)

Pfizer · FDA-approved active RNA therapeutics Quality 35/100

BNT162b4 15 mcg, marketed by Pfizer, is a leading COVID-19 preventive vaccine with a key composition patent expiring in 2028. Its primary competitive advantage lies in its established market presence and the robust mRNA technology platform. However, the primary risk is the intense competition from other vaccines, such as Moderna’s Spikevax and AstraZeneca’s Vaxzevria, which offer similar efficacy with varying dosage and stability conditions.

At a glance

Generic name	bnt162b4-15-mcg
Sponsor	Pfizer
Drug class	Unknown
Target	Unknown
Modality	RNA therapeutics
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

COVID-19 prevention

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Corticosteroids
Live vaccines
Interferon-alpha
Immunosuppressants
Thalidomide
Bacillus Calmette-Guérin (BCG) vaccine
Typhoid vaccine
Rabies vaccine
Influenza vaccine
Hepatitis A vaccine
Hepatitis B vaccine

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BNT162b4 15 mcg CI brief — competitive landscape report
BNT162b4 15 mcg updates RSS · CI watch RSS
Pfizer portfolio CI